![Lab Companies Turn to Product Integrations to Cut Costs, Risks, & Time](https://www.g2intelligence.com/wp-content/uploads/2023/03/April23.LIR_.DXDeals-iStock-1800x1250-1-1080x675.jpg)
Lab Companies Turn to Product Integrations to Cut Costs, Risks, & Time
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
Product integration collaborations have become increasingly common, with five such deals being announced between February and mid-March.
While only time will tell how bad the ultimate damage turns out to be, it appears for now at least that the industry has dodged a bullet.
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
Agency’s annual report to Congress concludes that providers are doing just fine and don’t need a big bump in pay at this time.
Current provider pay rates are “adequate,” says influential committee in its recent report to Congress.
U.S. Department of Health and Human Services secretary takes action to ensure continued access to COVID-19 EUA products.
Last week saw two key lab-related cases, with the biggest involving a fraud scheme relating to cancer genetic testing.
HHS orders arbitrators to go back to resolving payment disputes between providers and payors under the No Surprises Act.
To ensure proper Medicare Part B billing and coding, your billing staff must be aware of all 22 of the newly recognized PLA codes.
Proper usage of ABN-related modifiers is a significant issue that has a direct impact on your lab’s reimbursement and compliance.